These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8154520)

  • 1. Platelet GPIIb/IIIa antagonists: how safe is this antithrombotic approach?
    Mousa SA; De Grado WF; Reilly TM
    Am J Med; 1994 Mar; 96(3):300. PubMed ID: 8154520
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.
    Saucedo JF; Lui HK; Garza L; Guerra GJ; Jacoski MV; Jennings LK
    J Thromb Thrombolysis; 2004 Oct; 18(2):67-74. PubMed ID: 15789173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI.
    Deliargyris EN; Upadhya B; Melton LG; Thompson C; Fisher M; Gabriel DA; Dehmer GJ; Sane DC
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):458-64. PubMed ID: 17000891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
    Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
    Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
    J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

  • 18. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.
    Lincoff AM
    Circulation; 2003 Mar; 107(11):1556-9. PubMed ID: 12654616
    [No Abstract]   [Full Text] [Related]  

  • 19. New antiplatelet agents for acute coronary syndromes.
    Ferguson JJ; Lau TK
    Am Heart J; 1998 May; 135(5 Pt 2 Su):S194-200. PubMed ID: 9588400
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.